FULL INTEGRATED SCREEN PART I (MATERNAL SERUM)

Sample Reports
Sample Abnormal Report
Sample Normal Report

Test Documentation
Prenatal Screen Information Sheet

Components
Includes: Pregnancy Associated Plasma Protein-A (PAPP-A) and Nuchal Translucency (NT).
Risk assessment not reported until Full Integrated Screen Part II (Maternal Serum) is completed.

Specimen Required
Draw blood in a plain red-top tube. Centrifuge, separate serum from cells within 2 hours of collection and send 1.0 mL serum (0.6 mL minimum) frozen within 24 hours in a screw-capped plastic vial. The following information must be submitted: ultrasound date with CRL and NT measurement, ultrasonographer certification number from NTQR or FMF, maternal weight, maternal date of birth, insulin-dependent diabetes status prior to pregnancy, multiple gestation (single, twin, triplets), race, and previous history of Down syndrome or neural tube defect (NTD) pregnancy for the patient. Sample should be collected between 10 weeks 0 days (CRL 32 mm) and 13 weeks 6 days gestation (CRL 79.9 mm). Completed prenatal information sheet suppled by Client Services) must accompany sample.

Alternate Specimen
Serum: SST

Rejection Criteria
Moderately hemolyzed specimens

Methodology
Chemiluminescent Immunoenzymatic Assay

Stability
Room Temperature: Unacceptable; Refrigerated: 24 hours; Frozen: 14 days

Reference Range
By report

Performed
Monday-Friday

Turnaround Time4 days
Test CodeFI1NT
CPT-4 Code (s)
84163

Warde
Medical
Laboratory